Adding Seribantumab to Paclitaxel Fails to Improve PFS in Advanced Ovarian Cancer

Share this content:
Adding seribantumab, an immunoglobulin G2 monoclonal antibody that binds to HER3, to paclitaxel did not improve progression-free survival.
Adding seribantumab, an immunoglobulin G2 monoclonal antibody that binds to HER3, to paclitaxel did not improve progression-free survival.

Adding seribantumab, an immunoglobulin G2 monoclonal antibody that binds to HER3 (ErbB3), to paclitaxel did not improve progression-free survival compared with paclitaxel alone among unselected patients with advanced platinum-resistant or -refractory ovarian cancer, according to a study published in the Journal of Clinical Oncology.1

Preclinical data suggested that blocking heregulin (HRG)/ErbB3 may increase sensitivity to therapy when the phosphoinositide 3-kinase (PI3K)/Akt signaling pathway is active. Because seribantumab targets ErbB3 thereby blocking HRG from binding and downregulating the receptor, researchers evaluated the the efficacy and safety of seribantumab plus paclitaxel among patients with advanced ovarian cancer.

For the open-label, phase 2 study (ClinicalTrials.gov Identifier: NCT01447706), investigators enrolled 223 patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer resistant or refractory to platinum-based therapy. Participants were randomly assigned 2:1 to receive seribantumab plus paclitaxel or paclitaxel alone.

Median progression-free survival in the unselected intent-to-treat population was 3.75 months with seribantumab plus paclitaxel compared with 3.68 months with paclitaxel alone (hazard ratio [HR], 1.027; 95% CI, 0.741-1.425; P = .864), suggesting no significant difference in progression-free survival between the 2 arms.

Among the 57 patients whose tumors had detectable HRG mRNA and low HER2, the researchers observed a significant reduction in the risk of progression or death with seribantumab vs paclitaxel alone (HR, 0.37; 95% CI, 0.18-0.76; P = .007). In contrast, those who did not meet these criteria had a higher risk of progression or death (HR, 1.80; 95% CI, 1.08-2.98; P = .023).

RELATED: Niraparib Maintenance Prolongs PFS in Recurrent Ovarian Cancer

Although the study did not meet its primary endpoint of improved progression-free survival with the addition of seribantumab to paclitaxel, exploratory analyses demonstrated that patients with detectable HRG and low HER2 may particularly benefit from this combination. Further studies are warranted to validate this finding in this subpopulation of patients with advanced ovarian cancer.                     

Reference

  1. Liu JF, Ray-Coquard I, Selle F, et al. Randomized phase II trial of seribantumab in combination with paclitaxel in patients with advanced platinum-resistant or -refractory ovarian cancer. J Clin Oncol. 2016 Oct 23. doi: 10.1200/JCO.2016.67.1891 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters